Safe and Orally Bioavailable Inhibitor of Serine Palmitoyltransferase Improves Age-Related Sarcopenia
ACS Pharmacology & Translational Science · 10.01.2025 · 8 (1) · 203-215
DOI: 10.1021/acsptsci.4c00587 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Pharmacology & Translational Science, online erschienen am 29.12.2024. Verfasst von Johanne Poisson und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Integrative Systems Physiology, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne 1015, Switzerland. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HORIZON EUROPE European Research Council, Schweizerischer Nationalfonds zur F?rderung der Wissenschaftlichen Forschung, National Research Foundation of Korea.
Abstract (Originalsprache)
The accumulation of ceramides and related metabolites has emerged as a pivotal mechanism contributing to the onset of age-related diseases. However, small molecule inhibitors targeting the ceramide de novo synthesis pathway for clinical use are currently unavailable. We synthesized a safe and orally bioavailable inhibitor, termed ALT-007, targeting the rate-limiting enzyme of ceramide de novo synthesis, serine palmitoyltransferase (SPT). In a mouse model of age-related sarcopenia, ALT-007, administered through the diet, effectively restored muscle mass and function compromised by aging. Mechanistic studies revealed that ALT-007 enhances protein homeostasis in Caenorhabditis elegans and mouse models of aging and age-related diseases, such as sarcopenia and inclusion body myositis (IBM); this effect is mediated by a specific reduction in very-long chain 1-deoxy-sphingolipid species, which accumulate in both muscle and brain tissues of aged mice and in muscle cells from IBM patients. These findings unveil a promising therapeutic avenue for developing safe ceramide inhibitors to address age-related neuromuscular diseases.
Autor:innen und Institutionen
- Laboratory of Integrative Systems Physiology, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne 1015, Switzerland.
- Intonation Research Laboratories, Hyderabad 500076, India.
ORCID-Profile: Johan Auwerx
Förderung
- HORIZON EUROPE European Research Council
- Schweizerischer Nationalfonds zur F?rderung der Wissenschaftlichen Forschung
- National Research Foundation of Korea
- ?cole Polytechnique F?d?rale de Lausanne
Zitieren
APA
Poisson, J., Daskalaki, I., Potluri, V., Morel, J. D., Rodriguez-Lopez, S., De Masi, A., Benegiamo, G., Jain, S., Lima, T., & Auwerx, J. (2025). Safe and Orally Bioavailable Inhibitor of Serine Palmitoyltransferase Improves Age-Related Sarcopenia. ACS Pharmacology & Translational Science, 8(1), 203-215. https://doi.org/10.1021/acsptsci.4c00587
Vancouver
Poisson J, Daskalaki I, Potluri V, Morel JD, Rodriguez-Lopez S, De Masi A, et al. Safe and Orally Bioavailable Inhibitor of Serine Palmitoyltransferase Improves Age-Related Sarcopenia. ACS Pharmacology & Translational Science. 2025;8(1):203-215. doi:10.1021/acsptsci.4c00587
BibTeX
@article{Poisson2025,
author = {Poisson, Johanne and Daskalaki, Ioanna and Potluri, Vijay and Morel, Jean-David and Rodriguez-Lopez, Sandra and De Masi, Alessia and Benegiamo, Giorgia and Jain, Suresh and Lima, Tanes and Auwerx, Johan},
title = {Safe and Orally Bioavailable Inhibitor of Serine Palmitoyltransferase Improves Age-Related Sarcopenia},
journal = {ACS Pharmacology & Translational Science},
year = {2025},
volume = {8},
number = {1},
pages = {203--215},
doi = {10.1021/acsptsci.4c00587}
}
EUVIMED